EBV Clinical Trial
Official title:
Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics
1. To compare the therapeutic effects, safety and the corresponding pharmacokinetics and
pharmacodynamics between two different method of drug administration: 10mg, daily and
30mg/d, twice every week, and find out the more effect way of Chidamide administration.
2. To examine whether Chidamide could activate EB virus, and whether the above two
different ways of administration are different in EB virus activation.
Currently, Chidamide is taken twice a week, this comes from cell experiment and phase I
clinical trial, which showed that the de-acetylation effect of Chidamide could last for 72
hours after administration. However, daily administration of Chidamide may create a more
steady Chidamide concentration, thus improve the de-acetylation effect of Chidamide, so it's
necessary to compare the two different ways of administration.
Current study showed that Romidepsin, a HDACI, could activate EBV during the treatment of
NKTCL, whether Chidamide, as a novel HDACI, could activate EBV is still not clear, so this
problem is worth to be accessed.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01948180 -
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
|
Phase 2 | |
| Completed |
NCT01923766 -
Cytotoxic T Cells to Prevent Virus Infections
|
Phase 1 | |
| Terminated |
NCT03699904 -
Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial
|
Phase 2 | |
| Recruiting |
NCT01011712 -
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
|
||
| Active, not recruiting |
NCT04645147 -
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
|
Phase 1 | |
| Completed |
NCT02213068 -
Belatacept 3 Month Post Transplant Conversion Study
|
Phase 4 | |
| Terminated |
NCT02080416 -
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
|
Phase 0 | |
| Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
| Not yet recruiting |
NCT05677178 -
Response Prediction in EBV-HLH Using Metabonomics Analysis
|
||
| Completed |
NCT03650231 -
Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis
|
||
| Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
| Recruiting |
NCT02007356 -
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
|
Phase 2 | |
| Completed |
NCT03755440 -
PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.
|
Phase 2 | |
| Completed |
NCT03973723 -
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
|
||
| Completed |
NCT02318030 -
CNTRP POSITIVE Study
|